StoxGland Pharma vs Ipca Laboratories: share price & financials comparison
NSE: GLAND vs IPCALAB · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Gland Pharma vs Ipca Laboratories at a glance
Gland Pharma (GLAND) has a market capitalisation of ₹52,281 Cr, against ₹49,263 Cr for Ipca Laboratories (IPCALAB). Over the past year Gland Pharma has returned +66.4%, compared with +50.5% for Ipca Laboratories. On valuation, Ipca Laboratories trades at a lower P/E of 35.1 versus 46.3. Ipca Laboratories earns a higher return on equity (16.2% vs 10.9%). Gland Pharma comes out ahead on valuation, profitability, growth, financial health, momentum and technicals. Ipca Laboratories comes out ahead on size. Across the scored metrics below, Gland Pharma leads on 13 and Ipca Laboratories on 4. On StoxGud's 10-point checklist, Gland Pharma scores 9/10 and Ipca Laboratories scores 9/10.
| Metric | Gland Pharma | Ipca Laboratories |
|---|---|---|
| Size | ||
| Market cap | ₹52,281 Cr | ₹49,263 Cr |
| Revenue (latest FY) | ₹6,431 Cr | ₹9,646 Cr |
| Net profit (latest FY) | ₹1,027 Cr | ₹1,141 Cr |
| Valuation | ||
| P/E | 46.3 | 35.1 |
| P/B | 5.05 | 5.68 |
| Dividend yield | 0.57% | 0.11% |
| Profitability | ||
| Return on equity | 10.9% | 16.2% |
| Net profit margin | 16.8% | 13.4% |
| Operating margin | 26.0% | 22.5% |
| Growth | ||
| Revenue growth (YoY) | +19.6% | +13.8% |
| Net profit growth (YoY) | +47.1% | +32.8% |
| Revenue CAGR (multi-year) | +13.2% | +12.2% |
| Financial health | ||
| Debt to equity | 0.02 | 0.07 |
| Momentum | ||
| 1-month return | +0.6% | +0.2% |
| 1-year return | +66.4% | +50.5% |
| 3-year CAGR | +26.2% | +25.4% |
| 5-year CAGR | -2.8% | +12.9% |
| 10-year CAGR | — | +21.0% |
| Distance from 52W high | +0.0% | -3.4% |
| Technicals | ||
| RSI (14) | 60 | 65 |
| Price vs 200-day avg | +37.2% | +15.1% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Gland Pharma | Ipca Laboratories |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 9/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Gland Pharma or Ipca Laboratories?
Gland Pharma has a market cap of ₹52,281 Cr and Ipca Laboratories has a market cap of ₹49,263 Cr as of 06 Nov 2026.
Which has a lower P/E, Gland Pharma or Ipca Laboratories?
Ipca Laboratories has the lower P/E: Gland Pharma trades at 46.3 and Ipca Laboratories at 35.1.
Which gave better returns in the last year, Gland Pharma or Ipca Laboratories?
Gland Pharma did better: Gland Pharma returned +66.4% and Ipca Laboratories returned +50.5% over one year.
Is Gland Pharma or Ipca Laboratories a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Gland Pharma scores 9/10 and Ipca Laboratories scores 9/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.